A Practice-Based and Expert-Driven Consensus on the Management of Respiratory and Non-Respiratory Adverse Events Associated with Amikacin Liposome Inhalation Suspension (ALIS)

Authors

• C. Swenson, Emory University , Atlanta, GA
• C. Daley, National Jewish Health, Denver, CO
• J. Faber-Gerling, National Jewish Health, Denver, CO
• P.A. Flume, Medical University of South Carolina, Charleston, SC
• S.H. Kasperbauer, National Jewish Health, Denver, CO
• J. Kim, Georgetown University Hospital, Washington, D.C.
• A. Leitman, NTM Info & Research, Palmetto Bay, FL
• T. K. Marras, University of Toronto, Toronto, ON, Canada
• K. Morimoto, Fukujuji Hospital, Tokyo, Tokyo, Japan
• K. N. Olivier, University of North Carolina School of Medicine, Chapel Hill, NC
• K. L. Winthrop, OHSU-PSU School of Public Health, Portland, OR
• Juzar Ali, LSU Health Sciences Center - New OrleansFollow

Document Type

Conference Proceeding

Publication Date

1-11-2026

Publication Title

Open Forum Infectious Diseases

Abstract

IDWeek 2025, October 19-22, 2025, Atlanta, GA

First Page

S507

Volume

13

Issue

Supplement_1

Comments

Abstract #P-631

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Recommended Citation

Swenson, C.; Daley, C.; Faber-Gerling, J.; Flume, P.A.; Kasperbauer, S.H.; Kim, J.; Leitman, A.; Marras, T. K.; Morimoto, K.; Olivier, K. N.; Winthrop, K. L.; and Ali, Juzar, "A Practice-Based and Expert-Driven Consensus on the Management of Respiratory and Non-Respiratory Adverse Events Associated with Amikacin Liposome Inhalation Suspension (ALIS)" (2026). School of Medicine Faculty Publications. 5193.
https://digitalscholar.lsuhsc.edu/som_facpubs/5193
10.1093/ofid/ofaf695.844